Authors
Loading...
Randomised trial shows leukemia survival rates after secondary HSCT in patients with refractory AML, suggesting effective intervention options.
Wu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: